home / stock / lobef / lobef quote
Last: | $0.01675 |
---|---|
Change Percent: | 7.46% |
Open: | $0.0155 |
Close: | $0.01675 |
High: | $0.01675 |
Low: | $0.0155 |
Volume: | 19,348 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.01675 | $0.0155 | $0.01675 | $0.01675 | $0.0155 | 19,348 | 05-08-2024 |
$0.01675 | $0.0155 | $0.01675 | $0.01675 | $0.0155 | 1,166 | 05-07-2024 |
$0.018 | $0.018 | $0.018 | $0.018 | $0.018 | 8,600 | 05-06-2024 |
$0.0155 | $0.01575 | $0.0155 | $0.018 | $0.015 | 59,529 | 05-03-2024 |
$0.015 | $0.015 | $0.015 | $0.015 | $0.015 | 10,016 | 05-02-2024 |
$0.0146 | $0.0146 | $0.0146 | $0.0146 | $0.0146 | 1,516 | 05-01-2024 |
$0.0153 | $0.018 | $0.0153 | $0.018 | $0.01465 | 39,766 | 04-29-2024 |
$0.015 | $0.0135 | $0.015 | $0.0155 | $0.0135 | 68,888 | 04-26-2024 |
$0.0146 | $0.0146 | $0.0146 | $0.0146 | $0.0146 | 116 | 04-24-2024 |
$0.0144 | $0.01445 | $0.0144 | $0.01445 | $0.0135 | 3,040 | 04-23-2024 |
$0.01435 | $0.01435 | $0.01435 | $0.01435 | $0.01435 | 2,871 | 04-22-2024 |
$0.0152 | $0.015 | $0.0152 | $0.0152 | $0.01465 | 200,000 | 04-19-2024 |
$0.0153 | $0 | $0.0153 | $0 | $0 | 66 | 04-18-2024 |
$0.0153 | $0.013 | $0.0153 | $0.0153 | $0.013 | 11,000 | 04-17-2024 |
$0.013815 | $0.0121 | $0.013815 | $0.013815 | $0.0121 | 499 | 04-16-2024 |
$0.0154 | $0.0154 | $0.0154 | $0.0154 | $0.0154 | 51,000 | 04-15-2024 |
$0.0121 | $0.0136 | $0.0121 | $0.0136 | $0.0121 | 1,388 | 04-12-2024 |
$0.0137 | $0.0154 | $0.0137 | $0.0154 | $0.0137 | 20,033 | 04-11-2024 |
$0.0174 | $0.018 | $0.0174 | $0.018 | $0.012 | 54,128 | 04-10-2024 |
$0.015 | $0.015 | $0.015 | $0.015 | $0.015 | 42,607 | 04-09-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lobe Sciences Ltd Company Name:
LOBEF Stock Symbol:
OTCMKTS Market:
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.&nbs...
12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia ® Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"...
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformat...